BioStock: Lipum reports Q2 and increases the pace

In the report for the second quarter, biopharmaceutical company Lipum announces that they are increasing the pace of development of SOL-116 for rheumatoid arthritis. The clinical phase I study with the candidate is progressing according to plan and the company has identified a possibility to accelerate the second part of the study. With financial resources in place, the company looks forward to reporting results from the study in early 2024. 

Read the full article at biostock.se:

https://www.biostock.se/en/2023/09/lipum-reports-q2-and-increases-the-pace/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se